Drugs
Drug Groups Seek Changes to FDA's Distributed Manufacturing Rule
Three major pharmaceutical industry associations are urging FDA to revise its proposed distributed manufacturing rule to provide greater flexibility for existing multi-site manufacturing networks, clarify inspection and registration requirements, and avoid imposing additional regulatory burdens that could undermine drug supply-chain resilience. In 9/21 comments to the agency,